Immunocore Holdings Ltd
$ 31.69
0.70%
14 Apr - close price
- Market Cap 1,595,374,000 USD
- Current Price $ 31.69
- High / Low $ 32.12 / 31.44
- Stock P/E N/A
- Book Value 7.52
- EPS -0.71
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.02 %
- ROE -0.10 %
- 52 Week High 40.71
- 52 Week Low 27.06
About
Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. The company is headquartered in Abingdon, the United Kingdom.
Analyst Target Price
$63.86
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-04 | 2025-11-06 | 2025-08-07 | 2025-05-06 | 2025-02-26 | 2024-11-05 | 2024-08-08 | 2024-05-08 | 2024-02-28 | 2023-11-07 | 2023-08-10 | 2023-05-10 |
| Reported EPS | -0.6 | -0.0035 | -0.2 | -0.49 | -0.3714 | 0.17 | -0.23 | -0.49 | -32.22 | 4 | -0.37 | -35 |
| Estimated EPS | -0.197 | -0.24 | -0.18 | -0.36 | -0.1594 | -0.35 | -0.48 | -0.36 | -21.74 | -28.92 | -32.1 | -32.19 |
| Surprise | -0.403 | 0.2365 | -0.02 | -0.13 | -0.212 | 0.52 | 0.25 | -0.13 | -10.48 | 32.92 | 31.73 | -2.81 |
| Surprise Percentage | -204.5685% | 98.5417% | -11.1111% | -36.1111% | -132.9987% | 148.5714% | 52.0833% | -36.1111% | -48.2061% | 113.8313% | 98.8474% | -8.7294% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.26 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IMCR
2026-04-15 01:40:11
Immunocore (IMCR) has been upgraded to a "Strong Buy" rating by Zacks Investment Research, moving from a "Buy". This upgrade is based on strong upward estimate revisions for its earnings, following its recent earnings report that topped expectations. The company's stock shows potential for continued growth, trading at a reasonable valuation despite a significant surge over the past year.
2026-04-10 19:09:12
This article analyzes Immunocore Holdings Plc (IMCR), highlighting a prevailing positive sentiment that could extend long-term. It identifies a mid-channel oscillation pattern and presents an exceptional 42.7:1 risk-reward setup targeting a 12.7% gain with minimal risk. The article details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for near, mid, and long-term horizons.
2026-04-08 20:09:55
Immunocore Holdings Plc (IMCR) filed a Rule 144 notice to sell 25,000 ADRs through a "Same Day Cashless Exercise and Sale" with a trade date of April 8, 2026, and a settlement date of April 9, 2026. This filing also disclosed two previous ADR dispositions by David Berman in February and March 2026, totaling 17,797 ADRs. The market impact and sentiment are noted as neutral.
2026-04-06 20:10:48
Immunocore Holdings plc (Nasdaq: IMCR) announced that its management will participate in the 25th Annual Needham Virtual Healthcare Conference. The company, a commercial-stage biotechnology firm, specializes in immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases. The virtual fireside chat is scheduled for Monday, April 13, 2026, at 3:00 p.m. EDT, with a webcast available on Immunocore's investor relations website.
2026-04-06 11:10:17
Immunocore Holdings plc (Nasdaq: IMCR) announced its management will participate in the 25th Annual Needham Virtual Healthcare Conference. The company, a commercial-stage biotechnology firm specializing in immunomodulating medicines, will host a fireside chat on Monday, April 13, 2026, at 3:00 p.m. EDT. A live webcast and replay of the presentation will be available on Immunocore’s investor relations website.
2026-04-05 13:10:17
This article provides a technical analysis and stock price forecast for Immunocore Holdings PLC (IMCR). It indicates a 'Neutral' overall technical sentiment based on various indicators, with 5 buy and 6 sell signals. Key support and resistance levels are identified, and moving averages and momentum indicators like RSI and MACD are detailed, showing IMCR trading below its 60-day and 200-day moving averages.
